Clinical Trials Logo

Macular Edema clinical trials

View clinical trials related to Macular Edema.

Filter by:

NCT ID: NCT05736081 Completed - Clinical trials for Diabetic Macular Edema

Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema

Start date: February 15, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial es to learn about the short term effects of intravitreal dexamethasone implant (IDI) in patients with refractory diabetic macular edema. The main question it aims to answer is: How fast does the diminishing in central retinal thickness has statistical significance after IDI in patients with refractory diabetic macular edema? Patients will be evaluated by OCT before and after the implant.

NCT ID: NCT05731089 Completed - Clinical trials for Diabetic Macular Edema

IVI Aflibercept Before and After Phaco in DME.

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

To study whether or not cataract surgery should be deferred until treating the co-existing diabetic macular edema (DME) using intravitreal (IVI) anti-vascular endothelial growth factor (anti-VEGF).

NCT ID: NCT05728476 Recruiting - Clinical trials for Diabetic Macular Edema

Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema

Start date: March 5, 2024
Phase: N/A
Study type: Interventional

Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. At present, anti-vascular endothelial growth factor (VEGF) intravitreal injection is the first-line therapy for DME, nevertheless, some patients do not respond well to anti-VEGF agents and often require multiple injections, which increases the psychological and economic burden of patients. Microinvasive pars plana vitrectomy (PPV) has been proven to be safe and effective for refractory DME. However, there are few studies on treatment-naïve DME. The purpose of this study is to explore whether early PPV combined with internal limiting membrane (ILM) peeling can reduce the treatment burden of DME patients, prevent vision loss, and maintain long-term stabilization of diabetic retinopathy.

NCT ID: NCT05727891 Recruiting - Clinical trials for Diabetic Macular Edema

Evaluation of Tonabersat for DME

AN
Start date: May 2, 2023
Phase: Phase 2
Study type: Interventional

This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.

NCT ID: NCT05715385 Completed - Clinical trials for Diabetic Macular Edema

Comparison of Treatments in Diabetic Macular Edema

Start date: November 2014
Phase: Phase 4
Study type: Interventional

Prospective or cohort study to compare the effects of grid macular laser, topical bromfenac 0.09% and placebo (carboxymethyl cellulose 0.5%) medication in diabetic macular edema. 60 eyes with macular edema of two types i.e. cystoid macular edema (CME) and clinically significant macular edema (CSME) were divided into three groups with 20 patients in each group. One group was treated with grid laser photocoagulation, the second group was treated with topical bromfenac 0.09% drops two times a day and the third group was treated with topical carboxy methyl cellulose 0.5% three times a day (placebo treatment).

NCT ID: NCT05712720 Active, not recruiting - Clinical trials for Diabetic Macular Edema

Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

Start date: February 6, 2023
Phase: Phase 2
Study type: Interventional

The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with Diabetic Macular Edema.

NCT ID: NCT05699759 Recruiting - Clinical trials for Diabetic Macular Edema

Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects With Diabetic Macular Edema

Start date: January 4, 2024
Phase: Phase 1
Study type: Interventional

This study is designed to assess the safety and initial evidence of efficacy of the novel compound SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (DME).

NCT ID: NCT05698329 Recruiting - Clinical trials for Diabetic Macular Edema

Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME

Start date: March 2, 2023
Phase: Phase 1
Study type: Interventional

To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

NCT ID: NCT05697809 Active, not recruiting - Clinical trials for Diabetic Macular Edema

Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema

OXEYE
Start date: August 7, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone microspheres; DEXAspheres®) using the Oxulumis® illuminated microcatheterization device compared with intravitreal dexamethasone implant (OZURDEX®) in subjects with diabetic macular edema.

NCT ID: NCT05683912 Completed - Clinical trials for Diabetic Macular Edema

Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece

ADMIRE
Start date: September 1, 2019
Phase:
Study type: Observational

ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.